Allarity Therapeutics, Inc.

Develops personalized cancer drugs using a diagnostic platform to predict patient response.

ALLR | US

Overview

Corporate Details

ISIN(s):: US0167445008
LEI:
Country:: United States of America
Address:: 24 SCHOOL ST., 2ND FLOOR, 2108 BOSTON
Website:: https://allarity.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company focused on developing personalized cancer treatments. The company leverages its proprietary Drug Response Predictor (DRP®) technology, a diagnostic platform that analyzes tumor biology to predict a patient's response to specific therapies. This approach aims to refine patient selection and improve clinical outcomes for its pipeline of in-licensed oncology therapeutics. Allarity's lead clinical program is stenoparib, an orally available, dual-action small molecule inhibitor being advanced for patients with advanced recurrent ovarian cancer. The company's mission is to enhance patient outcomes through data-driven decision-making and personalized cancer care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allarity Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allarity Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allarity Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Pluri Inc. Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.	Israel	PLUR
PLUS THERAPEUTICS, INC. Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.	United States of America	PSTV
PMV Pharmaceuticals, Inc. Developing small molecule therapies targeting p53 mutations to treat cancer.	United States of America	PMVP
Polaris AI Pharma Corp. A global supplier of generic APIs using AI to accelerate drug development.	South Korea	041910
Poltreg S.A. Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.	Poland	PTG
PolyPeptide Group AG A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.	Switzerland	PPGN
PolyPid Ltd. Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.	United States of America	PYPD
Praxis Precision Medicines, Inc. Developing therapies for CNS disorders using insights from genetic epilepsies.	United States of America	PRAX
PRECIGEN, INC. Develops gene and cell therapies for difficult-to-treat diseases using precision technology.	United States of America	PGEN
Precipio, Inc. Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.	United States of America	PRPO